AI-first MindMaze emerges from $1.1 billion union of Relief and NeuroX

Swiss biotech Relief Therapeutics (SIX: RLF) has agreed to merge with privately held NeuroX Group in a transaction valuing NeuroX at 1 billion Swiss francs ($1.1 billion) and Relief at 100 million francs. The deal, expected to close in December, will create a publicly traded company focused on AI-driven neurology treatments.

The combined business will integrate pharmacological therapies with digital neurotherapeutics and a broad brain health platform. NeuroX brings a clinically validated portfolio already deployed in more than 250 clinics worldwide and backed by a US reimbursement code. Its digital suite has been tested in stroke, Parkinson’s disease and at-risk aging, with further research underway in multiple sclerosis, traumatic brain injury and dementia.

Following the transaction, Relief will be renamed MindMaze Therapeutics, with NeuroX founder Tej Tadi taking the helm as chief executive. Relief’s chief financial officer will retain his role, while vice-chairman Gregory Van Beek will remain on the board to ensure continuity.